Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
By combining
"With deep development and commercial expertise in oncology across a broad portfolio including multiple precision therapies for lung cancer,
"We are excited to enter into this collaboration with
While targeted therapies have improved treatment for patients with EGFR-driven NSCLC, resistance inevitably emerges, with the T790M and C797S mutations being highly common on-target resistance mechanisms. Designed to address these challenges, BLU-945 and BLU-701 have the potential to be used either as a monotherapy or in combination, together or with other agents, to overcome or prevent on-target resistance across multiple lines of treatment. In addition, this collaboration enables opportunities to combine BLU-945 or BLU-701 with other
BLU-945 is a selective, potent EGFR tyrosine kinase inhibitor with activity against EGFR activating mutations combined with the T790M and C797S resistance mutations. It is highly selective over wild-type EGFR and off-target kinases, highlighting its potential to enable tolerable combinations. BLU-945 is currently being evaluated in the Phase 1/2 SYMPHONY trial in patients with previously treated EGFR-driven NSCLC (NCT04862780). BLU-701 is a selective, potent EGFR tyrosine kinase inhibitor with activity against EGFR activating mutations combined with the C797S resistance mutation. It has shown significant central nervous system (CNS) penetration in preclinical studies, which is meaningful because in EGFR-mutant NSCLC patients with baseline brain metastases, up to 40 percent of disease progressions involve CNS metastases.5
Subject to the terms of the agreement,
About EGFR-Driven NSCLC in
Lung cancer is the most commonly diagnosed cancer type and the leading cause of cancer death in
About BLU-945 and BLU-701
Derived from
About
About
For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
Cautionary Note Regarding Blueprint Medicines' Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for
Zai Lab Forward-Looking Statements
This press release contains statements about future expectations, plans and prospects, including, without limitation, statements relating to the potential, benefits, safety and efficacy of BLU-945 and BLU-701; the clinical development of BLU-945 and BLU-701; the potential treatment of epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in
References
1 Zhang YL, Yuan JQ, Wang KF, et al. "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis". Oncotarget. 2016;7(48):78985-78993. doi:10.18632/oncotarget.12587
2 Zhou J, Song XB, He H, et al. "Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in
3 Wen S, Dai L, Wang L, et al. "Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell
4 International Agency for Research on Cancer, Estimated New Incidence in 2020, lung, both sexes, all ages. https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=countries&population=900&populations=900&key=total&sex=0&cancer=15&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0 Accessed
5 Rangachari D, Yamaguchi N, VanderLaan PA, et al. "Brain metastases in patients with EGFR-mutated or ALK-rearranged Non-Small Cell lung cancers".
6 Govindan R, Page N, Morgensztern D, et al. "Changing epidemiology of small-cell lung cancer in
Trademarks
All trademarks and registered trademarks referenced within are property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-and-zai-lab-announce-strategic-collaboration-and-license-agreement-for-blu-945-and-blu-701-in-greater-china-301419693.html
SOURCE
Blueprint Medicines Contacts, Media: Andrew Law, +1 (617) 844-8205, media@blueprintmedicines.com; Investor Relations: Kristin Hodous, +1 (617) 714-6674, ir@blueprintmedicines.com; Zai Lab Contacts, Investor Relations: Ron Aldridge, +1 (781) 434-8465, ronald.aldridge@zailaboratory.com; Lina Zhang, +86 136 8257 6943, lina.zhang@zailaboratory.com; Media: Danielle Halstrom, +1 (215) 280-3898, danielle.halstrom@zailaboratory.com; Xiaoyu Chen, +86 185 0015 5011, xiaoyu.chen@zailaboratory.com